NewAmsterdam Pharma (NAMS) Operating Margin (2023 - 2026)
NewAmsterdam Pharma (NAMS) posted Operating Margin of 1921.71% for Q1 2026, up 99.07% sequentially from 206187.5% in Q4 2025, and up 39276.0% YoY from N/an in Q1 2025.
Powered by 
Analysis
NewAmsterdam Pharma (NAMS) Operating Margin (2023 - 2026) Analysis & Trends
NewAmsterdam Pharma has reported Operating Margin for 4 years, with the latest figure at 1921.71% in Q1 2026.
- Quarterly Operating Margin rose 39276.0% year-over-year to 1921.71% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 953.59% (down 55111.0% YoY) and the FY2025 annual result came in at 1002.9%, down 61599.0% from the prior year.
- Operating Margin rose to 1921.71% in Q1 2026 per NAMS's latest filing, from 206187.5% in the prior quarter.
- Over five years, Operating Margin peaked at 85.89% in Q3 2024 and troughed at 206187.5% in Q4 2025.
- A 4-year average of 18779.11% and a median of 2306.93% in 2024 frame the typical range for Operating Margin.
- The sharpest annual moves came in 2024 and 2025: Operating Margin soared 602193 bps in 2024, then slumped 20584903 bps in 2025.
- Over 4 years, Operating Margin stood at 6360.4% in 2023, then soared by 95 bps to 338.47% in 2024, then sank by 60818 bps to 206187.5% in 2025, then jumped by 99 bps to 1921.71% in 2026.
- According to Business Quant data, Operating Margin over the past three periods registered 1921.71%, 206187.5%, and 15845.69% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -562.07% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 19.06% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 17.93% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 19.75% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.36% |
| 10 | NewAmsterdam Pharma | 3.13 Bn | 3.13 Bn | - | -1,752.61% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -1,752.61% |
| Mar 31, 2026 | -1,921.71% |
| Dec 31, 2025 | -206,187.50% |
| Sep 30, 2025 | -15,845.69% |
| Jun 30, 2025 | -186.13% |
| Mar 31, 2025 | -2,314.47% |
| Dec 31, 2024 | -338.47% |
| Sep 30, 2024 | -85.89% |
| Jun 30, 2024 | -2,306.93% |
| Mar 31, 2024 | -3,960.17% |
| Dec 31, 2023 | -6,360.40% |
| Sep 30, 2023 | -1,685.07% |
| Jun 30, 2023 | -2,474.20% |
| Mar 31, 2023 | -461.85% |